[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.241.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1977

TimololA β-Adrenergic Blocking Agent for the Treatment of Glaucoma

Author Affiliations

From the Department of Ophthalmology, College of Medicine, University of Florida, Gainesville.

Arch Ophthalmol. 1977;95(4):601-604. doi:10.1001/archopht.1977.04450040067008
Abstract

• Timolol maleate, a β-adrenergic blocking agent, was studied in 30 patients With glaucoma. Significant intraocular pressure lowering was achieved with 0.5% and 1.5% solution of the drug. At seven hours following treatment, the IOP was lowered 50% from the pretreatment pressure with both strengths of timolol. There Were no subjective or objective ocular or systemic side effects detected. Visual acuity and pupil response were unchanged from pretreatment levels throughout the study. β-Adrenergic blocking agents and specifically timolol may be an important breakthrough for the medical management of glaucoma.

(Arch Ophthalmol 95:601-604, 1977)

×